These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 26063904)

  • 1. Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
    Tisdale S; Pellizzoni L
    J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal Muscular Atrophy.
    Kolb SJ; Kissel JT
    Neurol Clin; 2015 Nov; 33(4):831-46. PubMed ID: 26515624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Variability in the Survival Motor Neuron Genes (
    Butchbach MER
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches for spinal muscular atrophy (SMA).
    Scoto M; Finkel RS; Mercuri E; Muntoni F
    Gene Ther; 2017 Sep; 24(9):514-519. PubMed ID: 28561813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy.
    Woo CJ; Maier VK; Davey R; Brennan J; Li G; Brothers J; Schwartz B; Gordo S; Kasper A; Okamoto TR; Johansson HE; Mandefro B; Sareen D; Bialek P; Chau BN; Bhat B; Bullough D; Barsoum J
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1509-E1518. PubMed ID: 28193854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal muscular atrophy: mechanisms and therapeutic strategies.
    Lorson CL; Rindt H; Shababi M
    Hum Mol Genet; 2010 Apr; 19(R1):R111-8. PubMed ID: 20392710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
    Sun Y; Grimmler M; Schwarzer V; Schoenen F; Fischer U; Wirth B
    Hum Mutat; 2005 Jan; 25(1):64-71. PubMed ID: 15580564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal muscular atrophy: diagnosis and management in a new therapeutic era.
    Arnold WD; Kassar D; Kissel JT
    Muscle Nerve; 2015 Feb; 51(2):157-67. PubMed ID: 25346245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients.
    Yamamoto T; Sato H; Lai PS; Nurputra DK; Harahap NI; Morikawa S; Nishimura N; Kurashige T; Ohshita T; Nakajima H; Yamada H; Nishida Y; Toda S; Takanashi J; Takeuchi A; Tohyama Y; Kubo Y; Saito K; Takeshima Y; Matsuo M; Nishio H
    Brain Dev; 2014 Nov; 36(10):914-20. PubMed ID: 24359787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.
    Zanetta C; Nizzardo M; Simone C; Monguzzi E; Bresolin N; Comi GP; Corti S
    Clin Ther; 2014 Jan; 36(1):128-40. PubMed ID: 24360800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease.
    Rao VK; Kapp D; Schroth M
    J Manag Care Spec Pharm; 2018 Dec; 24(12-a Suppl):S3-S16. PubMed ID: 30582825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.